213 related articles for article (PubMed ID: 36148773)
1. New potent ciprofloxacin-uracil conjugates as DNA gyrase and topoisomerase IV inhibitors against methicillin-resistant Staphylococcus aureus.
Samir M; Ramadan M; Abdelrahman MH; Elbastawesy MAI; Halby HM; Abdel-Aziz M; Abuo-Rahma GEA
Bioorg Med Chem; 2022 Nov; 73():117004. PubMed ID: 36148773
[TBL] [Abstract][Full Text] [Related]
2. Thiazolidine-2,4-dione-linked ciprofloxacin derivatives with broad-spectrum antibacterial, MRSA and topoisomerase inhibitory activities.
Aziz HA; El-Saghier AMM; Badr M; Abuo-Rahma GEA; Shoman ME
Mol Divers; 2022 Jun; 26(3):1743-1759. PubMed ID: 34455532
[TBL] [Abstract][Full Text] [Related]
3. An optimised series of substituted N-phenylpyrrolamides as DNA gyrase B inhibitors.
Tiz DB; Skok Ž; Durcik M; Tomašič T; Mašič LP; Ilaš J; Zega A; Draskovits G; Révész T; Nyerges Á; Pál C; Cruz CD; Tammela P; Žigon D; Kikelj D; Zidar N
Eur J Med Chem; 2019 Apr; 167():269-290. PubMed ID: 30776691
[TBL] [Abstract][Full Text] [Related]
4. Novel 1,2,4-oxadiazole-chalcone/oxime hybrids as potential antibacterial DNA gyrase inhibitors: Design, synthesis, ADMET prediction and molecular docking study.
Ibrahim TS; Almalki AJ; Moustafa AH; Allam RM; Abuo-Rahma GEA; El Subbagh HI; Mohamed MFA
Bioorg Chem; 2021 Jun; 111():104885. PubMed ID: 33838559
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and molecular docking of new N4-piperazinyl ciprofloxacin hybrids as antimicrobial DNA gyrase inhibitors.
Mohammed HHH; Ali DME; Badr M; Habib AGK; Mahmoud AM; Farhan SM; Gany SSHAE; Mohamad SA; Hayallah AM; Abbas SH; Abuo-Rahma GEA
Mol Divers; 2023 Aug; 27(4):1751-1765. PubMed ID: 36152132
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and antibacterial evaluation of new quinoline-1,3,4-oxadiazole and quinoline-1,2,4-triazole hybrids as potential inhibitors of DNA gyrase and topoisomerase IV.
Hofny HA; Mohamed MFA; Gomaa HAM; Abdel-Aziz SA; Youssif BGM; El-Koussi NA; Aboraia AS
Bioorg Chem; 2021 Jul; 112():104920. PubMed ID: 33910078
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of ciprofloxacin-sulfonamide hybrids to manipulate ciprofloxacin pharmacological qualities: Potency and side effects.
Ibrahim NM; Fahim SH; Hassan M; Farag AE; Georgey HH
Eur J Med Chem; 2022 Jan; 228():114021. PubMed ID: 34871841
[TBL] [Abstract][Full Text] [Related]
8. Dual inhibition of Staphylococcus aureus DNA gyrase and topoisomerase IV activity by phenylalanine-derived (Z)-5-arylmethylidene rhodanines.
Werner MM; Patel BA; Talele TT; Ashby CR; Li Z; Zauhar RJ
Bioorg Med Chem; 2015 Sep; 23(18):6125-37. PubMed ID: 26320664
[TBL] [Abstract][Full Text] [Related]
9. New 1,2,4-oxadiazole/pyrrolidine hybrids as topoisomerase IV and DNA gyrase inhibitors with promising antibacterial activity.
Frejat FOA; Cao Y; Wang L; Zhai H; Abdelazeem AH; Gomaa HAM; Youssif BGM; Wu C
Arch Pharm (Weinheim); 2022 Jul; 355(7):e2100516. PubMed ID: 35363388
[TBL] [Abstract][Full Text] [Related]
10. A new exploration toward adamantane derivatives as potential anti-MDR agents: Design, synthesis, antimicrobial, and radiosterilization activity as potential topoisomerase IV and DNA gyrase inhibitors.
Ragab A; Abusaif MS; Aboul-Magd DS; Wassel MMS; Elhagali GAM; Ammar YA
Drug Dev Res; 2022 Sep; 83(6):1305-1330. PubMed ID: 35716118
[TBL] [Abstract][Full Text] [Related]
11. Structure based design and synthesis of 3-(7-nitro-3-oxo-3,4-dihydroquinoxalin-2-yl)propanehydrazide derivatives as novel bacterial DNA-gyrase inhibitors: In-vitro, In-vivo, In-silico and SAR studies.
Saleh MA; Elmaaty AA; El Saeed HS; Saleh MM; Salah M; Ezz Eldin RR
Bioorg Chem; 2022 Dec; 129():106186. PubMed ID: 36215786
[TBL] [Abstract][Full Text] [Related]
12. Antistaphylococcal activities of the new fluoroquinolone JNJ-Q2.
Morrow BJ; Abbanat D; Baum EZ; Crespo-Carbone SM; Davies TA; He W; Shang W; Queenan AM; Lynch AS
Antimicrob Agents Chemother; 2011 Dec; 55(12):5512-21. PubMed ID: 21911562
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, in vitro antimicrobial evaluation and molecular docking studies of indol-2-one tagged with morpholinosulfonyl moiety as DNA gyrase inhibitors.
Salem MA; Ragab A; El-Khalafawy A; Makhlouf AH; Askar AA; Ammar YA
Bioorg Chem; 2020 Mar; 96():103619. PubMed ID: 32036161
[TBL] [Abstract][Full Text] [Related]
14. Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
Cheng J; Thanassi JA; Thoma CL; Bradbury BJ; Deshpande M; Pucci MJ
Antimicrob Agents Chemother; 2007 Jul; 51(7):2445-53. PubMed ID: 17502409
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of novel 2-aminobenzothiazole derivatives as potential antimicrobial agents with dual DNA gyrase/topoisomerase IV inhibition.
Ismail MMF; Abdulwahab HG; Nossier ES; El Menofy NG; Abdelkhalek BA
Bioorg Chem; 2020 Jan; 94():103437. PubMed ID: 31812260
[TBL] [Abstract][Full Text] [Related]
16. Sitafloxacin: antimicrobial activity against ciprofloxacin-selected laboratory mutants of Mycoplasma genitalium and inhibitory activity against its DNA gyrase and topoisomerase IV.
Deguchi T; Kikuchi M; Yasuda M; Ito S
J Infect Chemother; 2015 Jan; 21(1):74-5. PubMed ID: 25245990
[TBL] [Abstract][Full Text] [Related]
17. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
[TBL] [Abstract][Full Text] [Related]
18. Novel ciprofloxacin hybrids using biology oriented drug synthesis (BIODS) approach: Anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis, topoisomerase II inhibition, and antibacterial activity.
Kassab AE; Gedawy EM
Eur J Med Chem; 2018 Apr; 150():403-418. PubMed ID: 29547830
[TBL] [Abstract][Full Text] [Related]
19. Design, green one-pot synthesis and molecular docking study of novel N,N-bis(cyanoacetyl)hydrazines and bis-coumarins as effective inhibitors of DNA gyrase and topoisomerase IV.
Metwally NH; Abdallah SO; Mohsen MMA
Bioorg Chem; 2020 Apr; 97():103672. PubMed ID: 32145481
[TBL] [Abstract][Full Text] [Related]
20. New N-phenylpyrrolamide DNA gyrase B inhibitors: Optimization of efficacy and antibacterial activity.
Durcik M; Lovison D; Skok Ž; Durante Cruz C; Tammela P; Tomašič T; Benedetto Tiz D; Draskovits G; Nyerges Á; Pál C; Ilaš J; Peterlin Mašič L; Kikelj D; Zidar N
Eur J Med Chem; 2018 Jun; 154():117-132. PubMed ID: 29778894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
